搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
FierceBiotech
4 小时
Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2
Novo Nordisk’s $1 billion bet that it had found a cannabinoid CB1 receptor blocker that could reduce weight while avoiding ...
FierceBiotech
1 小时
Genfit moves to jump-start enrollment in slow-going phase 2 liver failure trial
Slow enrollment in a key clinical trial has driven Genfit to rework the protocol to try to keep the study on track. | Slow ...
FierceBiotech
2 小时
Chutes & Ladders—2 Kite vets fly over to Kyverna Therapeutics
Warren Biddle hit the exit from his role as SVP, global head of commercial at Gilead’s CAR-T unit Kite Pharma to take on the ...
FierceBiotech
3 小时
Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 ...
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...
FierceBiotech
6 小时
Edgewise's stock jumps 50% on the back of safety data for potential heart disease rival to ...
Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the ...
FierceBiotech
22 小时
Jury rules for Axonics in Medtronic’s long-running neuromodulation patent lawsuit
A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run ...
FierceBiotech
1 天
In 2 papers, researchers describe potential new neurodegenerative disease treatment approach
William McEwan, Ph.D., spent years unraveling how an antiviral protein, tripartite motif-containing 21 (TRIM21), protects our ...
FierceBiotech
1 天
Aligos' MASH prospect slashes liver fat in phase 2, but stock drops anyway
Aligos Therapeutics is heralding a midstage win in metabolic-dysfunction associated steatohepatitis (MASH) after three ...
FierceBiotech
1 天
Achilles drops cell therapy program, braces for layoffs after missing 'commercial viability ...
Achilles Therapeutics has torn up its strategy. The British biotech is stopping work on its clinical-phase cell therapy, ...
FierceBiotech
1 天
From 'science fiction to reality': New George Church-founded biotech raises $75M for cell ...
GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 ...
FierceBiotech
2 天
ESMO: Innovent links cytokine fusion protein to responses in colorectal cancer
Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.
FierceBiotech
1 天
NIH grants up to $100M yearly for pandemic preparedness network
With COVID-19 still spreading and mpox emerging as a public health emergency of international concern, the National ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈